NA 931
Alternative Names: BioGlutide; NA-931Latest Information Update: 24 Jul 2025
At a glance
- Originator Biomed Industries
- Class Neuroprotectants; Obesity therapies; Small molecules
- Mechanism of Action Gastric inhibitory polypeptide receptor agonists; Glucagon receptor agonists; Glucagon-like peptide-1 receptor agonists; Insulin-like growth factor I stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Obesity
- Preclinical Alcoholism
Most Recent Events
- 23 Jun 2025 Efficacy and adverse event data from phase II trial in Obesity released by Biomed Industries
- 20 Jun 2025 Efficacy and adverse events data from a phase I trial in Obesity presented at the 85th Annual Scientific Sessions of the American Diabetes Association (ADA-2025)
- 30 Apr 2025 Biomed completes a phase II trial in Obesity in Australia (PO)